ZFIN ID: ZDB-FISH-150901-9293
Fish name: vu16Tg
Genotype: vu16Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by vu16Tg
No data available
GENE EXPRESSION
Gene expression in vu16Tg
RNA expression
Expressed Gene Structure Conditions Figures
pkd2l1 standard conditions Fig. 7 from Djenoune et al., 2014
PHENOTYPE
Phenotype in vu16Tg
Phenotype Conditions Figures
dorsal longitudinal fasciculus axon ensheathment in central nervous system decreased process quality, abnormal chemical treatment: Ro 48-8071 Fig. 8 from Mathews et al., 2014
enteroendocrine cell decreased amount, abnormal germ free Fig. 1 with image from Troll et al., 2018
intestinal bulb peptide hormone secreting cell decreased amount, abnormal germ free Fig. 2 with image from Troll et al., 2018
oligodendrocyte development process quality, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
oligodendrocyte development process quality, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
protein farnesylation process quality, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
protein geranylgeranylation process quality, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
spinal cord central nervous system myelination process quality, normal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte dorsal to dorsal longitudinal fasciculus, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte dorsal to dorsal longitudinal fasciculus, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte mislocalised dorsally, abnormal chemical treatment: lonafarnib Fig. 5 from Mathews et al., 2014
spinal cord oligodendrocyte mislocalised dorsally, abnormal chemical treatment: GGTI-2133 Fig. 5 from Mathews et al., 2014

CITATIONS  (21)